NCT00478816已完成2 期
A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines
Novartis Vaccines1 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2007年5月最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- Cell-mediated immunity, magnitude, breath and kinetics of antibody response to 2 doses of MF59-adjuvanted H5N1 influenza vaccine, in subjects primed by previous vaccination with either MF59-adjuvanted or non-adjuvanted H5N3 influenza vaccine.
研究概览
简要总结
Valuate the immune response and reactogenicity of H5N1 vaccination in a primed population (H5N3 adjuvanted or non-adjuvanted vaccine) compared to immunologically naïve subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged 18 to 65 years of age, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol;
- •In good health as determined by:
- •medical history,
- •physical examination,
- •clinical judgment of the Investigator;
- •Subjects in the primed group previously received at least two doses of an H5N3 vaccine;
- •Able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for study visits.
排除标准
- •Receipt of another investigational agent within 4 weeks, or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another clinical study through the end of the study;
- •Subjects who experienced any acute disease or infection requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) within the past 7 days;
- •Subjects who experienced fever (defined as axillary temperature ≥38.0°C) within 3 days prior to Visit 1;
- •Subjects who are pregnant or breastfeeding;
- •Females of childbearing potential who refuse to use an acceptable method of birth control for the duration of the study. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD), or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject's study entry;
- •Subjects with any serious disease, such as:
- •autoimmune disease (including rheumatoid arthritis),
- •diabetes mellitus,
- •chronic pulmonary disease,
- •acute or progressive hepatic disease,
- •acute or progressive renal disease;
- •Subjects for whom a surgery is planned during the study period;
- •Subjects with bleeding diathesis;
- •Subjects with hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine;
- •Subjects with a history of any neurological symptoms or signs, or anaphylactic shock following administration of any vaccine;
- •Subjects with known or suspected impairment/alteration of immune function, for example, resulting from:
- •receipt of immunosuppressive therapy (any corticosteroid therapy or cancer chemotherapy),
- •receipt of immunostimulants,
- •receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visit 1 or planned during the full length of the study,
- •high risk for developing an immunocompromising disease;
- •Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination;
- •Subjects with a history of (or current) drug or alcohol abuse that in the investigator's opinion would interfere with safety of the subject or the evaluation of study objectives;
- •Subjects with any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.
结局指标
主要结局
Cell-mediated immunity, magnitude, breath and kinetics of antibody response to 2 doses of MF59-adjuvanted H5N1 influenza vaccine, in subjects primed by previous vaccination with either MF59-adjuvanted or non-adjuvanted H5N3 influenza vaccine.
时间窗: Days 1, 8, 15, 22, 43 and 202
次要结局
- Safety Objectives: safety and reactogenicity of the vaccine(Days 1, 8, 15, 22, 43 and 202)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In AdultsHealthyNCT01250795Fraunhofer, Center for Molecular Biotechnology100
已完成
2 期
Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and AboveInfluenzaNCT00620815Novartis Vaccines601
已完成
2 期
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 YearsProphylaxis of Avian InfluenzaNCT00537524Novartis Vaccines471
已完成
1 期
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in AdultsAvian InfluenzaInfluenzaNCT00895544Resilience Government Services, Inc.231
已完成
2 期
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult SubjectsPandemicAvian InfluenzaNCT00481065Novartis405